Search results
The FDA Could, Finally, Approve Novavax's Covid Vaccine — Is Novavax Stock A Buy?
Investor's Business Daily· 2 days agoNovavax stock isn't a buy. Savvy investors are encouraged to buy a stock after it breaks out of a...
Novavax seeks FDA nod for updated COVID-19 vaccine By Investing.com
Investing.com· 14 hours agoNovavax , Inc. (NASDAQ: NASDAQ:NVAX) has announced its submission for an amended Emergency Use...
Is It Too Late to Buy Novavax Stock?
Motley Fool via Yahoo Finance· 1 day agoThose concerns are now alleviated as Novavax has agreed to refund up to $475 million. More recently, there was news that Novavax entered ...
Novavax (NASDAQ:NVAX) Shares Gap Down to $19.56
ETF DAILY NEWS· 6 days agoShares of Novavax, Inc. (NASDAQ:NVAX – Get Free Report) gapped down before the market opened on Friday . The stock had previously closed at $19.56, but opened at $18.79. & ...
COVID summer guide: How to navigate symptoms, variants and vaccines this season
Yahoo Life· 2 days agoBut the good news is that the newly dominant variants don’t appear more likely to cause severe...
Novavax And Agios Pharmaceuticals Were Among The 10 Biggest Mid-Cap Gainers Last Week (June 1-June...
Benzinga· 6 days agoMid-cap stocks saw significant gains last week, with top performers like AGIO, VRNT, and NVAX,...
FDA Tells Vaccine Makers to Target New COVID Variant for Fall
WFMZ Eastern Pennsylvania and Western New Jersey· 22 hours agoCOVID vaccine makers will be advised to update their shots to target the KP.2 variant, an offshoot...
COVID Variant KP.3 Surges to Dominance—Here's What You Need to Know
Health via Yahoo News· 2 days agoPer Zambrano, all three COVID vaccine manufacturers—Pfizer, Moderna, and Novavax—have said that...
Moderna's combination Covid, flu vaccine is more effective than existing shots in late-stage trial
NBC Miami· 5 days agoModerna said its combination vaccine targeting Covid and the flu was more effective than existing...
Takeda circles a leukemia drug; J.P. Morgan moves into biotech investing
BioPharma Dive via Yahoo Finance· 21 hours agoThe Japanese pharma paid $100 million to secure option rights to an Ascentage drug. Elsewhere, J.P....